[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100456267":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":17,"responsibleParty":32,"collaborators":7,"id":35,"slug":36,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":40,"acronym":41,"eligibilityCriteria":42,"healthyVolunteers":37,"sex":43,"minAge":44,"maxAge":7,"enrollmentInfo":45,"targetDuration":48,"studyType":49,"phases":7,"briefSummary":50,"conditions":51,"keywords":7,"overallStatus":20,"whyStopped":7,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},{"fullName":5,"class":6},"Erasmus Medical Center","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Anne-Marie Dingemans, MD, PhD","PRINCIPAL_INVESTIGATOR",[13],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},"CONTACT","+31107040704","a.dingemans@erasmusmc.nl",[18],{"facility":19,"status":20,"city":21,"state":7,"zip":7,"country":22,"countryCode":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":30},"Erasmus MC","RECRUITING","Rotterdam","Netherlands","NL",{"type":25,"coordinates":26},"Point",[27,28],4.47917,51.9225,{"lat":28,"lon":27},[31],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},{"type":11,"investigatorFullName":33,"investigatorTitle":34,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Anne-Marie Dingemans","MD, PhD","100456267","prospective-sampling-in-driver-mutation-pulmonary-oncology-patients-on-tyrosine-kinase-inhibitors-start-tki-100456267",false,"NCT05221372","ProSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors (START-TKI)","proSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors","START-TKI","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Able to understand the written informed and able to give informed consent\n* Locally advanced or metastatic NSCLC with oncogenic driver mutation\n* Treatment with TKI according to standard of care\n\nExclusion Criteria:\n\n* Unable to draw blood for study purposes","ALL","18 Years",{"count":46,"type":47},1300,"ESTIMATED","10 Years","OBSERVATIONAL","The study is perfomed with adult patients with non-small cell lung cancer treated with tyrosine kinase inhibitor. The objective is to collect repeated samples of blood from patients (starting) on a tyrosine kinase inhibitor, for liquid mutation testing, and pharmacokinetic analysis.",[52,53,54],"Non Small Cell Lung Cancer","Liquid Biopsy","Tyrosine Kinase Inhibitor","2022-02-02",{"date":57,"type":58},"2022-02-18","ACTUAL",{"date":60,"type":58},"2017-02-02",{"date":62,"type":47},"2031-01-01",{"name":5,"class":6},1]